The companies’ icotrokinra, or JNJ-2113, significantly cleared skin compared to placebo in patients with moderate to severe ...
Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback